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vated, however, and therefore could not sig-
nal transcription of androgen-dependent
genes, which disrupted sexual development.
Vinclozolin was the first chemical reported
to have an anti-androgenic effect.
The EPA investigators and molecular
biologists from the University of North
Carolina at Chapel Hill began to compare
their data with Guilette's and months later
invited Guilette to the EPA to examine the
results. The team found that DDE, the pri-
mary metabolite ofDDT, shrunk sex organs
in male rats by up to 20% in four days. And
pregnant rats exposed to DDE gave birth to
male rats with female sexual characteristics.
Guilette and the rest of the scientific
world were surprised by the results, pub-
lished in Nature on June 15. "There was
quite significant binding that helps explain
what we saw in the alligators," says Guilette.
"I'm rethinking the whole concept of hor-
mone receptor specificity. It's much more
complex than we realized." Guilette noted
that because some minor isomers of DDT
are clearly estrogenic, DDT and its metabo-
lites are now known to affect both estrogenic
and androgenic hormone action.
DDE's anti-androgenic effects may help
explain recent adverse changes in male repro-
ductive health, such as decreasing sperm
counts in various parts of the world, and
increases in testicular cancer and cases of
abnormal development of the penis and
testis. The work also raises the question of
how chemicals can actsimultaneously as ago-
nists and antagonists for both estrogen and
androgen, says Kenneth Korach, an NIEHS
researcher who was involved in creating an
estrogen knock-out mouse. Elizabeth
Wilson, a University of North Carolina at
Chapel Hill investigator workingwith Kelce,
is researching whether the androgen receptor
forms a heterodimer, binding both DDE
and androgen. The dose response of DDE
would be critical in this case, she says.
Although DDT was banned in the
United States in 1973, DDT and its meta-
bolites persist in the environment (it has a
half-life of up to 100 years), and it is still
used to control malaria in some countries
such as Mexico and Brazil, and in some areas
ofAfrica.
The EPA/UNC team reported that the
concentration of DDE needed to inhibit
androgen receptor transcriptional activity in
cell culture or to affect newborn rat pups is
analogous to levels found in other instances
of DDT contamination including Guilette's
Florida alligator eggs and in kidneys ofstill-
born babies in the United States in the mid-
1960s, when DDTwas still being used.
Scientifically, the study offers more ques-
tions than answers. It raises the issue of the
adequacy of testing manufactured chemicals
for hormonally active compounds. "Past reg-
ulatory testing was insensitive to these kinds
ofproblems," says Kelce. "We are only now
beginning to appreciate what tests need to be
conducted."
Guilette also wonders about the effect
ofan anti-androgen on females: "Ifit mod-
ifies the estrogen-androgen ratio in
women, increasing their estrogen, it could
result in increased breast cancer and like
diseases." Kelce says he has identified 20
other chemicals that have anti-androgenic
effects. Although he says he can't release
the list yet, he indicated that none ofthem
is currently banned.
The Immortality Enzyme
Telomerase, an enzyme that gives some cells
a permanent stay of execution, appears to
play a role in lung cancer progression,
according to a study in the June 25 issue of
the Journal ofthe National Cancer Institute.
Jerry Shay and his colleagues at the
University of Texas Southwestern Medical
Center at Dallas and at the Hiroshima
University School ofMedicine found telom-
erase activity in approximately 80% of the
136 primary lung cancer tissues they tested,
versus only about 4% of68 adjacent normal
tissue samples. Ofthe 136 primary lung can-
cer samples, all 11 ofthe small cell lung can-
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Inwarandfootball, it'soften saidthat the bestdefense is agoodoffense. This same philoso-
phy is the basis for-a World Wide Web site aimed at improving the environment through
pollution prevention. Enviro$en$e (URL:http://wastenot.inel.gov:80/envirosense/), which
is maintained at the Idaho National Engineering Laboratory, is funded bythe EPAand the
StrategicEnvironmental Research and Development Proeram (SERDP), ajointeffortofthe
Department ofDefense, the Department
of Energy, and the EPA that supports
environmental quality research, develop-
ment, demonstration, and applications
programs.
Eight hyperlinks on the Enviro$en$e
homepage offer a vast array ofinforma-
tion in categories such as news and
resources, pollution prevention programs
-.,
from the local to the federal level, international programs, technical research and develop-
ment, compliance andenforcement, and more.
For example, the news hyperlink connects users to information such as a Pollution
Prevention Directory, several hodines and clearinghouses, the National Consortium for
Environmental Education andTraining's Environmental Education Link (agopher site that
offers access to teaching resources including instructional materials, articles, databases, and
grantinformation), andtheNational Pollution Prevention Centerfor HigherEducation.
Federal laws, regulations, environmental activities, and presidential executive orders, and
both state and local pollution prevention servers may be accessed through another hyper-
link. The international resources hyperlink provides information on pollution prevention
programs around the world by connecting to organizations such as the U.S. Agency for
International Development's Environmental Prevention Protection Project, the Montreal
Protocol (protection of ozone layer), the North American Free Trade Agreement, the
Organization for Economic Cooperation and Development, and the United Nations
Environment Program.
The technical research and development hyperlink provides access to case studies and
fact sheets on EPA studies of commercial companies, as well as environmental research
briefs, project summaries, and pollution prevention assessments. This link also connects
to the EPA Office ofResearch and Development and a pollution prevention publications
bibliography.
Perhaps the most innovative element of the site is an interactive search function that
allows users to query the Solvent Alternatives Guide (SAGE), the Hazardous Solvent
Substitution Data System (HSSDS), and the Department ofDefense Pollution Prevention
Technical Library. SAGE is alogic-tree system that evaluates a manufacturer's current oper-
ating scenario and then identifies possible alternative surface-cleaning solvent chemistries
and processes that best suit the operating and material requirements. HSSDS is an on-line
system ofinformation on alternatives to hazardous solvents that contains product informa-
tion, material safety data sheets, and other related information. Also available on this site is
access to the Department ofDefense Ozone DepletingChemical/ Substance Information.
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cers (SCLC) showed telomerase activity,
while telomerase activity varied in non-small
cell lung cancers (NSCLC).
Normally, telomerase is inactive in somat-
ic cells, which die naturally after a number of
cell divisions. Each time a chromosome is
reproduced, the telomere, a small part at the
end of the chromosome, is lost. In order to
counter these losses, each of the chromo-
some's telomeres carries repeating nucleotide
sequences. However, once those sequences are
used up, the cell stops dividing and dies. Cells
that need to continue to reproduce, such as
germ line reproductive cells, carry telomerase,
a DNA polymerase which adds repeating
nucleotide sequences to the shortened telom-
eres. Previous studies have also found telom-
erase activity in malignant
tumors of numerous cell types
including breast, prostate,
colon, skin, and brain, suggest-
ing that the enzyme allows can-
cercells to continue todivide.
The reactivation of telom-
erase may occur at either of
two stages of cell death, mor-
tality stage 1 (MI) or mortali-
ty stage 2 (M2). During MI,
cells lose their ability to divide,
a state known as senescence.
The malfunction of a tumor-
suppressor gene or the muta-
tion of an oncogene might
transform a cell, allowing it to
avoid senescence. However,
although such defects extend
the cell's life span, it will even-
tually die. During M2, cells
reach a point known as crisis,
in which most cells die; how-
ever, the survivors are immortal and capable
ofunlimited proliferation.
The presence ofNSCLC tumors contain-
ing both mortal and immortal cells suggests
that the immortalization ofan existing tumor
cell is rare, requiring two separate events and
occurring after manycell divisions. In SCLCs,
cells show signs ofhaving already undergone
the number of divisions and chromosomal
changes necessary for the reactivation of
telomerase before becoming cancerous.
Shay and his colleagues observed varia-
tions in telomerase activity that may reflect
characteristics ofthe cells or the ratio ofmor-
tal to immortal cells within the tumors.
However, although levels oftelomerase activi-
ty varied dramatically among some of the
samples tested, immortalized lung cancer cell
lines all showed similar activity, whether
SCLC or NSCLC. The study's authors cau-
tiously suggest that once a lung cell is immor-
talized, it achieves a set level of telomerase
activity no matterwhat its type.
The absence oftelomerase activity in some
tumors may indicate that they consist entirely
ofmortal cells. A previous study, published in
Science, found that benign fibroid tumors did
not have telomerase activity. According to
Shay's study, "Ifcancers that have mortal cells
exist, their growth might be self-limiting in
contrastto thosethatconsistofimmortal cells,"
apossible reasonwhySCLCsarethemostdiffi-
cult lung cancers to treat. This distinction
between cellpopulations withtelomerase activi-
ty and those without it may serve as the basis
fortests to predict thecells' capacityfor contin-
ued proliferation and, therefore, the disease's
severity. Telomerase activity might even be
found in cells obtained from a patient's lung
wash, a procedure Shay used in his study and
one which is already commonly used for other
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Solid gold silos? Two containers atthe Fernald nuclear plant, slated for clean-
up, hold medically priceless amounts of radium.
typesoflungcancerdiagnostic tests.
Researchers are already searching for a
drug that inhibits telomerase, in hopes ofcut-
ting short the lives of the most proliferative
lung cancer cells. In the August 31 issue of
Science, researcher Calvin B. Harley ofGeron
Corporation andhis colleagues at ColdSpring
Harbor Laboratory reported that they were
able to produce reverse RNA that blocked the
action oftelomeraseandcaused HeLacells, an
experimental cancer cell line, to begin dying
after 23-26 cell divisions. While Harley
emphasizes that a drug able to mimic this
effectmaytakeyears to findanddevelop, such
a drug could prevent the spread of cancer
without harming normal cells. In an interview
with the Associated Press, Shay said, "This is
the first laboratory proof that inhibiting of
telomerase RNA will result in limiting cell
division.... This is the most important next
step in telomerase research."
In an earlier AP interview Shay pointed
out that the existence of metastatic tumors
lacking telomerase activity implies that there
are other immortalization mechanisms.
According to molecular epidemiologist Curtis
Harris of the National Cancer Institute, a
mechanism that enabled cells to escape senes-
cence would be one that bypasses the problem
ofshrinking telomeres, such as DNArecombi-
nation, probably avery inefficient mechanism.
Ifdrugs were developed to target telomerase,
these alternate mechanisms ofimmortalization
might come into play to allow tumor cells to
escape senescence, says Harris. Even in those
cells where telomerase inhibitors successfully
prevented immortalization, any remaining
supply of telomeric repeats would allow the
cell to continue to divide for a finite period of
time, with possible adverse consequences to
the patient. In addition, other cells in the
body, such as stem cells and stomach
cells, might be sensitive to telomerase
inhibitors, leading to serious side
effects.
What a Waste
It may seem unusual for U.S. scien-
tists and medical researchers to lobby
strongly against a government pro-
gram to clean up the contaminated
Fernald nuclear plant in Ohio, but
that's exactly what's happening. The
Fernald plant, which processed ura-
nium for nuclear weapons from
1951 to 1989, now has about
10,000 tons of radioactive waste
contained in two special silos.
Within this waste, however, is a
medically priceless stockpile of radi-
um as well as millions of dollars
worth of gold and other precious
metals. Scientists are arguing that
this radium, which is scheduled to be dis-
posed ofstarting in early 1996, may be criti-
cal to saving the lives ofcancer patients ifa
clinical trial that attempts to cure cancer with
a radium-based monoclonal antibody is suc-
cessful.
David Scheinberg, a medical oncologist
at the Memorial Sloan Kettering Cancer
Center, is enrolling patients in a clinical trial
to test a new methodology that links a radi-
um-based isotope, bismuth-213, to a mono-
clonal antibody to target cancer cells. The
treatment is being tested on 10-20 patients
who have acute myeloid leukemia (AML) or
chronic myeloid leukemia (CML). In a pre-
liminary experiment using a leukemia mouse
model, the bismuth-213 antibody treatment
led to remission of the diseases and longer
survival rates. If the phase I trial scheduled
for November is successful, it will be fol-
lowed by a slightly larger study within a year
ofthe phase I results. Iffurther clinical trials
show positive results and the treatment is
approved by the FDA, it could potentially be
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